Integrative Cancer Epidemiology Programme
More than 330,000 people are diagnosed with cancer each year in the UK, and more than 40% of these cases are linked to a combination of 14 major lifestyle and other factors. ICEP is funded by Cancer Research UK (CRUK) to investigate the molecular epidemiology of cancer in an effort to reduce its impact on society.
Cancers of the breast, lung, prostate and bowel account for over half of all new cancer cases. In this programme we aim to reduce the burden of cancer by identifying risk factors, mechanisms and predictive biomarkers that will inform diagnosis and treatment of several different cancers.
This is an interdisciplinary and multicentre research programme based within the MRC Integrative Epidemiology Unit and School of Social and Community Medicine at the University of Bristol. The programme involves 16 investigators and many more collaborators across four schools at the University of Bristol, the International Agency for Research on Cancer (IARC), the University of Manchester and the University of Oxford.
ICEP aligns closely with CRUK strategic priorities, specifically to:
- Increase investment in prevention research
- Increase investment in early diagnosis
- Optimise survival via precision medicine
- Develop future cancer research leaders
Academic Administrator: Lisa Wright email@example.com 0117 3314025
- Integrate high-throughput ‘omics’ platforms with large-scale cancer epidemiology to identify:
- Causal targets for intervention (WP 1)
- Metabolomic and epigenetic biomarkers (WP 2)
- Mechanisms underpinning causal associations (WP 3)
- Cross cutting strands
- Knowledge transfer